Our fair value estimate for narrow-moat Shenzhen Inovance 300124 remains at CNY 64 per share after the company reported third-quarter results that were largely on track with our full-year projections.
BIO-key sees 2025 growth with 20% higher license revenue and enhanced focus on proprietary solutions
Management expects revenue growth and improved profitability in 2025, driven by increased adoption of proprietary solutions and expanded customer interest, particularly in cybersecurity-enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results